401 related articles for article (PubMed ID: 30042077)
1. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
Schneider-Thoma J; Efthimiou O; Huhn M; Krause M; Reichelt L; Röder H; Davis JM; Salanti G; Leucht S
Lancet Psychiatry; 2018 Aug; 5(8):653-663. PubMed ID: 30042077
[TBL] [Abstract][Full Text] [Related]
2. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis.
Schneider-Thoma J; Efthimiou O; Bighelli I; Dörries C; Huhn M; Krause M; Reichelt L; Röder H; Furukawa TA; Davis JM; Leucht S
Lancet Psychiatry; 2019 Sep; 6(9):753-765. PubMed ID: 31320283
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Leucht S; Tardy M; Komossa K; Heres S; Kissling W; Salanti G; Davis JM
Lancet; 2012 Jun; 379(9831):2063-71. PubMed ID: 22560607
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M; Nikolakopoulou A; Schneider-Thoma J; Krause M; Samara M; Peter N; Arndt T; Bäckers L; Rothe P; Cipriani A; Davis J; Salanti G; Leucht S
Lancet; 2019 Sep; 394(10202):939-951. PubMed ID: 31303314
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
Zhu Y; Krause M; Huhn M; Rothe P; Schneider-Thoma J; Chaimani A; Li C; Davis JM; Leucht S
Lancet Psychiatry; 2017 Sep; 4(9):694-705. PubMed ID: 28736102
[TBL] [Abstract][Full Text] [Related]
9. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole alone or in combination for acute mania.
Brown R; Taylor MJ; Geddes J
Cochrane Database Syst Rev; 2013 Dec; (12):CD005000. PubMed ID: 24346956
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole for schizophrenia.
El-Sayeh HG; Morganti C
Cochrane Database Syst Rev; 2004; (2):CD004578. PubMed ID: 15106256
[TBL] [Abstract][Full Text] [Related]
12. Acupuncture for schizophrenia.
Shen X; Xia J; Adams CE
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005475. PubMed ID: 25330045
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.
Bighelli I; Rodolico A; García-Mieres H; Pitschel-Walz G; Hansen WP; Schneider-Thoma J; Siafis S; Wu H; Wang D; Salanti G; Furukawa TA; Barbui C; Leucht S
Lancet Psychiatry; 2021 Nov; 8(11):969-980. PubMed ID: 34653393
[TBL] [Abstract][Full Text] [Related]
14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole versus placebo for schizophrenia.
Belgamwar RB; El-Sayeh HG
Cochrane Database Syst Rev; 2011 Aug; (8):CD006622. PubMed ID: 21833956
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.
McGirr A; Vöhringer PA; Ghaemi SN; Lam RW; Yatham LN
Lancet Psychiatry; 2016 Dec; 3(12):1138-1146. PubMed ID: 28100425
[TBL] [Abstract][Full Text] [Related]
18. Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials.
Schneider-Thoma J; Kapfhammer A; Wang D; Bighelli I; Siafis S; Wu H; Hansen WP; Davis JM; Salanti G; Leucht S
Syst Rev; 2021 Aug; 10(1):214. PubMed ID: 34340713
[TBL] [Abstract][Full Text] [Related]
19. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole versus typicals for schizophrenia.
Bhattacharjee J; El-Sayeh HG
Cochrane Database Syst Rev; 2008 Jan; (1):CD006617. PubMed ID: 18254107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
